Intermediate Neurofilament Antibody Panel (NF-L, NF-M,NF-H) Reference: ARG30145 Intermediate Neurofilament antibody; Neurofilament NF-H antibody; Neurofilament NF-L antibody; Neurofilament NF-M antibody
Elotuzumab Reference: HY-P9965 Elotuzumab is a monoclonal antibody directed against the SLAMF7 receptor. Elotuzumab has no significant antimyeloma activity when given as a single agent with relapsed or refractory multiple myeloma (RRMM). Elotuzumab results in improved response and outcome when combined with other antimyeloma agents.
Sampeginterferon beta-1a Reference: HY-P99897 Sampeginterferon beta-1a (BCD-054) is a pegylated IFNβ-1a. Sampeginterferon beta-1a can be used for research against remitting multiple sclerosis.
Glucose uptake: Insulin Receptor Dependent Pathway Antibody Panel (GLUT4, AKT... Reference: ARG30151 Glucose uptake: Insulin Receptor Dependent Pathway antibody; Akt phospho (Ser473) antibody; IRS1 phospho (Ser636) antibody; GLUT4 antibody
Pulocimab Reference: HY-P99808 Pulocimab is an anti-VEGFR2 monoclonal antibody (mAb). Pulocimab can be used for the research of cancers.
Suprachiasmatic Nuclei (SCN) Marker Antibody Duo Reference: ARG30154 VIP protein belongs to the glucagon family. It stimulates myocardial contractility, causes vasodilation, increases glycogenolysis, lowers arterial blood pressure and relaxes the smooth muscle of trachea, stomach and gall bladder. The protein also acts as an antimicrobial peptide with antibacterial and antifungal activity. Alternative splicing occurs at this locus and two transcript variants encoding distinct isoforms have been identified. [provided by RefSeq, Nov 2014]Arginine vasopressin (AVP), also known as vasopressin, argipressin or antidiuretic hormone (ADH), is a hormone found in most mammals, including humans. Vasopressin is a peptide hormone that controls the reabsorption of molecules in the tubules of the kidneys by affecting the tissue's permeability. It also increases peripheral vascular resistance, which in turn increases arterial blood pressure. It plays a key role in homeostasis, and the regulation of water, glucose, and salts in the blood. It is derived from a preprohormone precursor that is synthesized in the hypothalamus and stored in vesicles at the posterior pituitary. Most of it is stored in the posterior pituitary to be released into the bloodstream. However, some AVP is also released directly into the brain.
Anti-Mouse CD11a Antibody Reference: HY-P99120 Anti-Mouse CD11a Antibody is an anti-mouse CD11a IgG2b antibody inhibitor derived from the host Rat.
Phospho Smad1 for Activation / Inhibition site Antibody Panel Reference: ARG30155 Phospho Smad1 for Activation / Inhibition site antibody; Smad 1 antibody; Smad 1 phospho (Ser465) antibody; Smad 1 phospho (Ser206) antibody
Etanercept Reference: HY-108847 Etanercept, a dimeric fusion protein that binds TNF, acts as a TNF inhibitor. Etanercept competitively inhibits the binding of both TNF-α and TNF-β to cell surface TNF receptors, rendering TNF biologically inactive. Etanercept shows efficacy against rheumatoid arthritis, juvenile idiopathic arthritis, and plaque psoriasis.
Talacotuzumab Reference: HY-P99395 Talacotuzumab (JNJ 56022473; CSL 362) is an IgG1-type fully humanized, CD123-neutralizing monoclonal antibody containing a modified Fc structure. Talacotuzumab has KDs of 0.43 nM, 188 nM, 46 nM, 16.8 nM for CD123, CD32b/c, CD16-158F, CD16-158V, respectively. Talacotuzumab inhibits IL-3 binding to CD123, antagonizing IL-3 signaling in target cells. Talacotuzumab has mutated the Fc region to increase affinity for CD16 (FcγRIIIa), thereby enhancing antibody-dependent cell-mediated cytotoxicity (ADCC). Talacotuzumab is highly effective in vivo reducing leukemic cell growth in acute myeloid leukemia (AML) xenograft mouse models.